The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.
1. The pharmacokinetics of dermatan sulphate MF701 were studied in 12 healthy males after administration of single intravenous bolus (200 mg), intramuscular (100 and 300 mg) and oral (1 g) doses. The study was conducted according to a within-subject crossover design in two paired blocks. 2. Plasma drug concentrations were measured using a competitive binding assay and a range of biological activity assays, including a sensitive catalysed thrombin inhibition test. 3. Following intravenous administration, plasma concentrations of dermatan sulphate determined by competitive binding assay were described by a two-compartment open model with an initial t1/2, in of 0.6 h and a t1/2,z of 7.5 h. Biological activity assays were insufficiently sensitive to detect the second phase, and therefore yielded apparent monoexponential kinetics. 4. After intramuscular injection the apparent bioavailability of dermatan sulphate was 16-20%. Plasma drug concentrations increased in proportion to dose when measured by competitive binding assay. Low concentrations persisted for more than 24 h at the higher dose, and these may prove therapeutically relevant on chronic administration. 5. We confirm that dermatan sulphate is the only glycosaminoglycan known to generate significant plasma concentrations following oral administration. Oral bioavailability was estimated to be 7%.
Dawes
J
J
Heart Research Institute, Sydney, Australia.
McLaren
M
M
Forbes
C
C
Belch
J J
JJ
Lane
D A
DA
Bray
B
B
McEwen
J
J
Houin
G
G
Gianese
F
F
D000293:Adolescent; D000328:Adult; D001667:Binding, Competitive; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D004333:Drug Administration Routes; D006801:Humans; D008297:Male; D012016:Reference Values
D003871:Dermatan Sulfate